ReviewCureus2026
Insulin Deintensification After Glucagon-Like Peptide-1 (GLP-1)-Based Therapy in Type 2 Diabetes: Evidence and a Practical Clinical Framework.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glucagon-like peptide-1 (GLP-1)-based therapies have changed the management of insulin-treated type 2 diabetes by creating opportunities not only to improve glycemic control and body weight but also to reduce insulin exposure and simplify previously intensified treatment regimens. However, clinical guidance remains considerably clearer on when to initiate or intensify insulin than on how to safely reduce established insulin therapy after effective GLP-1-based treatment is introduced. This narrative clinical review examines evidence for insulin dose reduction, regimen simplification, prandial insulin withdrawal, and complete insulin withdrawal following initiation or intensification of GLP-1-based therapy in adults with type 2 diabetes. Randomized trials and real-world studies increasingly support simplification of complex insulin regimens, with the strongest direct evidence supporting reduction or withdrawal of prandial insulin in appropriately selected patients. Complete insulin withdrawal is achievable in some individuals but remains less extensively studied. A practical approach should distinguish basal from prandial insulin and integrate overall glycemic control with fasting and postprandial glucose patterns, hypoglycemia risk, current insulin requirements, and clinical features suggesting impaired endogenous insulin reserve. Continuous glucose monitoring or structured glucose monitoring can facilitate sequential adjustment as GLP-1-based therapy is titrated. Patients with marked hyperglycemia, previous ketosis or diabetic ketoacidosis, suspected autoimmune diabetes, or other evidence of clinically important insulin deficiency require greater caution. We propose an evidence-informed phenotype-based framework in which insulin components are progressively reassessed rather than routinely continued or withdrawn according to a fixed formula. The objective is not insulin independence itself, but identification of the least complex insulin regimen necessary to maintain safe, individualized glycemic control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.